4 views left Get unlimited views with a free account

Take your business to the next level. Explore the latest trends and actionable insights to inform business strategy and pinpoint opportunities and risks.

Number of ongoing Clinical Trials (for drugs) involving Myelodysplastic Syndrome by Phase

Industry: Pharmaceuticals
Current: Other Industry Indicators

There are currently 1391 ongoing clinical trials involving Myelodysplastic Syndrome
Of the 1391 trials,343 trials are in Phase II
Furthermore, 302 trials are in Phase I

Number of ongoing Clinical Trials (for drugs) involving Myelodysplastic Syndrome by Phase

View as table

The global pharmaceutical industry is steadily developing new drugs for Myelodysplastic Syndrome, an oncology indication. The largest number of ongoing clinical trials for Myelodysplastic Syndrome is conducted in North America. Asia-Pacific and Europe are among some of the other prominent regions engaged in Myelodysplastic Syndrome-related drug trials.

University of Texas MD Anderson Cancer Center: The leading ongoing Myelodysplastic Syndrome related clinical trial sponsor

University of Texas MD Anderson Cancer Center is the top sponsor for Myelodysplastic Syndrome-related ongoing clinical trials.

National Cancer Institute US, Fred Hutchinson Cancer Research Center, Celgene Corp, Fred Hutchinson/University of Washington Cancer Consortium, and City of Hope are among other notable clinical trial sponsors involved in Myelodysplastic Syndrome. A clinical trial sponsor can be a Company, Government, Individual, or Institution.

Marketed Drugs involving Myelodysplastic Syndrome

Lenalidomide (Revlimid), Imatinib mesylate (Gleevec/ Zuciel/ QTI571/ Glivec/ Glivec GIST), and Azacitidine (Vidaza, Azafuridine, Celazadine) are among the key marketed drugs involving Myelodysplastic Syndrome.

Lenalidomide (Revlimid) is a thalidomide analogue and an immunomodulatory imide drug (IMiD). It functions via Protein Cereblon (CRBN) Activator mechanism of action.  It is formulated as hard gelatin capsules for oral route of administration. Revlimid Syndrome is marketed for the treatment of Myelodysplastic Syndrome and several other indications including T-Cell Leukemia, Follicular Lymphoma, Multiple Myeloma (Kahler Disease), Myelodysplastic Syndrome, T-Cell Lymphomas, Extranodal Marginal Zone B-Cell Lymphoma (Mucosa-Associated Lymphoid Tissue or MALT-Lymphoma), Mantle Cell Lymphoma, Marginal Zone B-cell Lymphoma, Nodal Marginal Zone B-Cell Lymphoma. Lenalidomide was first approved in 2005 and is marketed globally including the US, the UK, Australia, France, Germany, China, and Japan by Bristol-Myers Squibb Co and its subsidiaries.

Imatinib mesylate (Gleevec/ Zuciel/ QTI571/ Glivec/ Glivec GIST) is an anti-neoplastic agent. It functions via Bcr-Abl Tyrosine Kinase (EC 2.7.10.2) Inhibitor mechanism of action. It is formulated as hard gelatin capsules, tablets, coated tablets and film coated tablets for oral route of administration. Imatinib mesylate is marketed for the treatment of Myelodysplastic Syndrome and several other indications including Dermatofibrosarcoma Protuberans (DFSP), Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), Gastrointestinal Stromal Tumor (GIST), Myeloproliferative Disorders. Imatinib mesylate was first approved in 2001 and is marketed globally including the US, the UK, Australia, France, Germany, China, and Japan by Novartis AG and its subsidiaries.